Niagen Bioscience (NAGE) Accounts Payables (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Accounts Payables data on file, last reported at $13.3 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 24.88% year-over-year to $13.3 million in Q1 2026; TTM through Mar 2026 was $13.3 million, a 24.88% increase from a year earlier, with the FY2025 full-year figure at $10.8 million, up 26.62% from the prior year.
• Accounts Payables for Q1 2026 stood at $13.3 million, up from $10.8 million in the prior quarter.
• Over the last five years, Accounts Payables for NAGE reached as high as $13.7 million in Q2 2025 and fell as low as $6.9 million in Q3 2024.
• Historically, Accounts Payables has averaged $10.0 million across 5 years, with a median of $9.8 million in 2022.
• Across the five-year window, Accounts Payables dropped 24.95% in 2024 and soared 84.59% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $9.7 million in 2022, then increased by 5.71% to $10.2 million in 2023, then decreased by 16.67% to $8.5 million in 2024, then gained by 26.62% to $10.8 million in 2025, then advanced by 22.98% to $13.3 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $13.3 million in Q1 2026, $10.8 million in Q4 2025, and $12.7 million in Q3 2025.